Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00072358
Recruitment Status : Active, not recruiting
First Posted : November 6, 2003
Last Update Posted : October 4, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center